KKKulparshan Kubenova

Kulparshan Kubenova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kulparshan Kubenova has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prospective External Validation of the HFA-ICOS Baseline Cardiovascular Risk Classification in Women with Breast Cancer Receiving Anthracycline-Containing Therapy in a Central Asian Cohort

    by Aiganym Amanova, Bekbolat Zholdin, Saule Balmagambetova, Iliada Talipova, Gulnara Kurmanalina, Saule Madinova, Mira Baspayeva, Kulparshan Kubenova, Gulmira Sultanbekova, Maria Poltavskaya, et al.

    Background/Objectives: The HFA-ICOS baseline cardiovascular risk classification was developed to standardize pretreatment risk stratification before potentially cardiotoxic cancer therapy, but its external performance across diverse populations remains incompletely characterized. We prospectively evaluated its performance in women with breast cancer receiving anthracycline-containing therapy in Central Asia. Methods: This prospective single-center external validation study used data from the PREDICATE cohort (ISRCTN12628444). Participants were classified at baseline as being at low, moderate, high, or very high cardiovascular risk according to the HFA-ICOS classification before treatment and outcome ascertainment; the high- and very-high-risk categories were pooled for analysis because of small numbers. Participants underwent serial cardiovascular surveillance, including echocardiographic assessment of left ventricular ejection fraction and global longitudinal strain, together with serial cardiac biomarker measurements. The primary outcome was cancer therapy-related cardiac dysfunction (CTRCD), defined according to the 2022 ESC cardio-oncology criteria. Results: The analysis included 108 participants. CTRCD occurred in 43 of 108 participants (39.8%). The observed proportion of participants who developed CTRCD increased from 30.0% in the low-risk group to 47.5% in the moderate-risk group and 75.0% in the high/very-high-risk group (p = 0.026). Kaplan–Meier analysis demonstrated significant separation of CTRCD-free survival across HFA-ICOS risk categories (log-rank χ2 = 10.12; p = 0.006). Compared with the low-risk group, the hazard of CTRCD was higher in the moderate-risk group (hazard ratio [HR], 2.16; 95% confidence interval [CI], 1.13–4.13) and high/very-high-risk group (HR, 3.59; 95% CI, 1.42–9.11). Discrimination was modest (area under the curve, 0.630; 95% CI, 0.530–0.724). Conclusions: The HFA-ICOS classification demonstrated a clear ordinal gradient in CTRCD risk and significant time-to-event separation but showed limited discrimination at the individual-patient level. It may guide initial risk stratification but should be complemented by longitudinal cardiovascular surveillance rather than used as a stand-alone predictor.

  • Open Access

    Role of Clinical Risk Factors and B-Type Natriuretic Peptide in Assessing the Risk of Asymptomatic Cardiotoxicity in Breast Cancer Patients in Kazakhstan

    by Zhenisgul Tlegenova, Saule Balmagambetova, Bekbolat Zholdin, Gulnara Kurmanalina, Iliada Talipova, Arip Koyshybaev, Gulmira Sultanbekova, Mira Baspayeva, Saule Madinova, Kulparshan Kubenova, et al.

    The asymptomatic progression of chemotherapy-induced cardiotoxicity poses a significant risk to breast cancer patients. In the present single-center cohort study, a predictive model for evaluating the risk of cardiotoxicity during or by the end of chemotherapy was designed. The risk-prediction nomogram was delineated and assessed. In total, 34 patients out of 120 developed asymptomatic cardiotoxicity (28.3%). Of six explored biomarkers, only B-type natriuretic peptide showed a reliable pattern of incremental increase, revealing statistical significance between cardiotoxicity “+” and “−” groups by visit 4 or by the 9th month of monitoring (p 0.006). The following predictors were included in the model: age, hypertension, diabetes mellitus, baseline glomerular filtration rate, 6 min walk test measured at visit 4, BNP values at visit 4, left ventricular ejection fraction levels at visit 4, a total dose of radiotherapy received, and anthracycline cumulative doses. The model’s AUC was 0.72 (95% CI 0.59; 0.86), evidencing the satisfactory predictive ability of the model; sensitivity 100% (95% CI 90.36; 100.0) at a specificity of 66.67% (95% CI 50.33; 79.79); PPV 54.1% [95% CI 47.13; 60.91]; PVN 100% [95% CI 94.64; 100.00]. The calibration plot showed satisfactory agreement between predicted and actual chances (p = 0.98). The designed model can be applied in settings lacking speckle tracking echocardiography.


  • Open Access

    Early Diagnosis of Chemotherapy-Linked Cardiotoxicity in Breast Cancer Patients Using Conventional Biomarker Panel: A Prospective Study Protocol

    by Saule Balmagambetova, Zhenisgul Tlegenova, Bekbolat Zholdin, Gulnara Kurmanalina, Iliada Talipova, Arip Koyshybaev, Dinara Nurmanova, Gulmira Sultanbekova, Mira Baspayeva, Saule Madinova, et al.

    The prognosis of cancer treatment depends on, among other aspects, the cardiotoxicity of chemotherapy. This research aims to create a feasible algorithm for the early diagnosis of antitumor therapy cardiotoxicity in breast cancer patients. The paper represents a protocol for a prospective cohort study with N 120 eligible participants admitted for treatment with anthracyclines and/or trastuzumab. These patients will be allocated into four risk groups regarding potential cardiotoxic complications. Patients will be examined five times every three months for six biomarkers: cardiac troponin I (cTnI), brain natriuretic peptide (BNP), C-reactive protein (CRP), myeloperoxidase (MPO), galectin-3 (Gal-3), and D-dimer, simultaneously with echocardiographic methods, including speckle tracking. The adjusted relative risk (aOR) of interrupting an entire course of chemotherapy due to cardiotoxic events will be assessed using multiple analyses of proportional Cox risks. The Cox model will also assess associations between baseline biomarker values and time to cardiotoxic events. Moreover, partly conditional survival models will be applied to determine associations between repeated assessments of changes in biomarkers from baseline and time to cancer therapy-related cardiac dysfunction. All models will be adjusted for cancer therapy regimen, baseline LVEF, groups at risk, baseline biomarker values, and age. The decision-tree and principal component analysis (PCA) methods will also be applied. Thus, feasible patterns will be detected.